Acute Myeloid Leukemia Refractory Clinical Trial
Official title:
Infusion of ex Vivo-generated Allogeneic Natural Killer Cells in Combination With Subcutaneous IL-2 in Patients With Acute Myeloid Leukemia: a Phase I/IIa Study
This study investigates an innovative treatment for relapsed or refractory acute myeloid leukemia exploiting administration of ex vivo-generated allogeneic natural killer (NK) cells with preceding non-myeloablative conditioning chemotherapy with or without subsequent in vivo IL-2 cytokine support.
This study investigates an innovative treatment for relapsed or refractory acute myeloid leukemia (AML) exploiting administration of ex vivo-generated allogeneic natural killer (NK) cells with preceding non-myeloablative conditioning chemotherapy with or without subsequent in vivo IL-2 cytokine support. This is a prospective phase I/IIa study. The first phase is a IL-2 dose-escalating safety study in twelve patients. The second phase of the study is designed as a Simon's optimal two-stage single-arm phase IIa study, comprising seventeen patients. Prior to NK cell infusion, all patients will receive cyclophosphamide and fludarabine (Cy/Flu) based lymphodepleting chemotherapy. On day 0, all patients will receive a fixed dose of 1.0-3.0 x 10^9 allogeneic umbilical cord blood-derived NK cells (UCB-NK cells). These cells are generated ex vivo from CD34+ hematopoietic progenitor cells obtained from an allogeneic UCB unit. In phase I of the study patients will receive UCB-NK cells without subcutaneous (SC) IL-2, with lower dose SC IL-2 or with higher dose SC IL-2 (n=3 per treatment group, n=6 in the highest tolerable dose). After establishing the safety of UCB-NK cells combined with SC IL-2, we will continue with phase IIa of the study, with ten patients in the first stage (including the six patients from phase I with comparable IL-2 dose) and if clinical efficacy is achieved an additional seven patients in the second stage. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05574608 -
Allogenic CD123-CAR-NK Cells in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia
|
Early Phase 1 | |
| Recruiting |
NCT06125652 -
Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05105152 -
PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML
|
Phase 1 | |
| Recruiting |
NCT05546580 -
Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)
|
Phase 1 | |
| Recruiting |
NCT05317403 -
Venetoclax to Augment Epigenetic Modification and Chemotherapy
|
Phase 1 | |
| Recruiting |
NCT05211570 -
AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
|
Phase 1/Phase 2 | |
| Terminated |
NCT03690154 -
A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML
|
Phase 1 | |
| Not yet recruiting |
NCT05854966 -
CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
|
Phase 2 | |
| Recruiting |
NCT05506332 -
Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia
|
Phase 1 | |
| Recruiting |
NCT05949125 -
Dose-escalating Trial With Allo-RevCAR01-T Cells in Combination With CD123 Target Module (R-TM123) for Participants With Selected Hematologic Malignancies Positive for CD123
|
Phase 1 | |
| Recruiting |
NCT06128044 -
CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia
|
Phase 1 | |
| Not yet recruiting |
NCT06281847 -
An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06150040 -
Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX]
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06201247 -
Off-the-shelf CD123 CAR-NK for R/R AML
|
Early Phase 1 | |
| Recruiting |
NCT04914845 -
KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia
|
Phase 1 | |
| Recruiting |
NCT06017258 -
A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia
|
Phase 1 | |
| Recruiting |
NCT05190471 -
A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)
|
Phase 1 | |
| Recruiting |
NCT06297941 -
Study of REM-422 in Patients With AML or Higher Risk MDS
|
Phase 1 | |
| Not yet recruiting |
NCT06372717 -
A Study to Investigate APL-4098 Alone and/or in Combination With Azacitidine in R/R AML and High-Risk MDS
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05488132 -
Administration of Anti-siglec-6 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)
|
Phase 1/Phase 2 |